Home › Upcoming votes › IRulya Therapeutics Inc.
This meeting took place on October 6, 2026. IRulya Therapeutics Inc. reported the official results on Form 8-K, filed October 6, 2026 (read it on EDGAR); they are listed below.
Read the proxy statement on EDGAR
Ballot read from the proxy statement and checked. As listed in IRulya Therapeutics Inc.’s proxy statement, with the board’s recommendation on each item. The company has filed 1 set of additional materials since; they can add to or change what is below, so check them before relying on it.
| # | Item | Proposed by | Board recommends | Last year (same kind of item) |
|---|---|---|---|---|
| 1 | APPROVAL OF ISSUANCE OF COMMON STOCK UPON CONVERSION OF SERIES C PREFERRED STOCK AND EXERCISE OF THE WARRANTS AND ORPHAI OPTIONS, WHICH (A) WILL REPRESENT MORE THAN 20% OF THE SHARES OF COMMON STOCK OUTSTANDING PURSUANT | Board | For | — |
| 2 | APPROVAL OF ISSUANCE OF SHARES OF OUR COMMON STOCK UPON CONVERSION OF THE PIPE PREFERRED SHARES AND UPON EXERCISE OF THE PIPE WARRANTS PURSUANT TO NASDAQ LISTING RULE 5635(D) | Board | For | — |
| 3 | APPROVAL OF AMENDMENT OF THE CERTIFICATE OF INCORPORATION TO INCREASE THE NUMBER OF AUTHORIZED SHARES OF COMMON STOCK FROM 250,000,000 TO 275,000,000 | Board | For | — |
| 4 | APPROVAL OF THE 2026 EQUITY INCENTIVE PLAN | Board | For | — |
| 5 | APPROVAL OF THE 2026 ESPP | Board | For | — |
| 6 | APPROVAL OF ADJOURNMENT OR POSTPONEMENT OF THE SPECIAL MEETING TO A LATER DATE OR DATES, IF NECESSARY, TO SOLICIT VOTES FOR PROPOSALS NOS. 1, 2 AND/OR Adjournment |
Board | For | — |
From IRulya Therapeutics Inc.’s Form 8-K, filed June 5, 2025, for the meeting held June 4, 2025 (read it on EDGAR). Support is the share of votes cast that were FOR: abstentions and broker non-votes are left out.
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Elect Director: June Bray | 88% | — |
| Elect Director: Christopher J. Senner | 93% | — |
| Elect Director: Rajiv Patni, M.D. | 93% | — |
| 2. Approval of Amendment to the Certificate of Incorporation to increase the total number of authorized shares of the Company's common stock | 88% | Approved |
| 3. Approval of Amendment to the Certificate of Incorporation to Effect a Reverse Stock Split | 89% | Approved |
| 4. Ratification of Selection of Independent Registered Accounting Firm | 96% | Approved |
| 5. Approval, on an advisory basis, of the compensation of the Company's named executive officers | 95% | Approved |
| Item | Support (of votes cast) | Reported outcome |
|---|---|---|
| Proposal 1: . The voting results set forth below for Proposal No. 1 reflect the subtraction of 162,971 shares of common stock from the votes | 97% | Approved |
| 2. Approval of the issuance of shares of common stock, upon conversion of Series C Preferred Stock and upon exercise of warrants to purchase | 98% | Approved |
| 3. Approval of an amendment to the Company's certificate of incorporation to increase the number of authorized shares of Common Stock from 2 | 98% | Approved |
| 4. Approval of the 2026 Plan. The votes cast | 86% | Approved |
| 5. Approval of the 2026 ESPP. The votes cast | 87% | Approved |
The meeting facts and ballot come from the SEC proxy filings listed above. Ballots are read from the proxy statement and checked against the filing’s own text; when that check does not pass, the page shows “see the proxy statement” instead of a ballot. Last year’s figures are the company’s official Form 8-K results and the managers’ Form N-PX reports. Nothing on this page predicts how any shareholder will vote, and it is not investment advice. How this works.